Prof. Tak W. Mak: The Multifaceted Challenges and Collaborative Innovation in TCR Clinical Translation—From Target Selection to Combination Strategies | CTI 2025
To advance innovation in China’s cell and immunotherapy landscape, deepen exchanges on key scientific questions, and share the latest clinical research progress, the 2025 International Cell and Immunotherapy Conference (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Society of Immunology, and the Zhejiang Anti-Cancer Association, and co-hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and the Liangzhu Laboratory—was held in Hangzhou, Zhejiang, from November 13 to 16, 2025.
EBMT President-Elect Prof. Ibrahim Yakoub-Agha: A New Dimension in MDS Management — Genomics, Transplant Timing, and Future Directions | ICCI 2025
To promote innovation in China’s cell and immunotherapy fields, facilitate in-depth exchange on key scientific issues, share the latest clinical research progress, and advance global collaboration and clinical translation, the…
CTI 2025 Expert Interview | Prof. Norbert Claude Gorin
We are pleased to share a featured interview from the Cellular Therapy and Immunotherapy Conference 2025 (CTI 2025) in Hangzhou, conducted in collaboration with Hematology Frontier. In this in-depth discussion,…
Professor Edmund Waller: Blocking VIP Signaling and Advancing CAR-T Therapy | Academic Exchange at Peking University Institute of Hematology
On November 2, 2025, Professors Michael R. Bishop, M.D. and Edmund Waller visited the Peking University Institute of Hematology for an academic exchange that included ward rounds, keynote lectures, and…
Professor Michael R. Bishop Visits Peking University Institute of Hematology: Advancing CAR-T Therapy and Strengthening Global Collaboration
On November 2, 2025, Professor Michael R. Bishop, M.D. visited the Peking University Institute of Hematology for clinical rounds, a keynote lecture, and focused exchanges on the future of cellular…
Dr. YishanYe: Continued Validation of the Advantages of Haploidentical Transplantation — Moving Toward an Era of “Timely Access to Optimal Donors for All” | 2025 International Cell & Immunotherapy Congress
To promote innovation in China’s cell therapy and immunotherapy fields, advance discussion of key scientific challenges, share the latest clinical research, and strengthen global collaboration and translational progress, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Immunology Society, and the Zhejiang Anti-Cancer Association—was held on November 13–16, 2025 in Hangzhou.
Blood Science Update|China Expert Consensus on mNGS for Diagnosing Infections in Hematological Disorders (2024)
The 2024 China Expert Consensus on metagenomic next-generation sequencing (mNGS) in hematological disorders, published in Blood Science, offers the first national guidance on how mNGS should be applied to infection diagnosis in this highly vulnerable population. Because hematological diseases and their treatments cause profound immunosuppression, infections remain a major cause of morbidity and mortality. Traditional microbiological tests (CMTs) frequently produce delayed or negative results, especially after antibiotic exposure. mNGS, which enables broad, unbiased pathogen detection, has therefore become an essential complementary tool.